Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warburg closes $4.5bn Bausch & Lomb buyout:

This article was originally published in Clinica

Executive Summary

Yesterday saw the start of a new chapter in the 154-year history of ophthalmic company Bausch & Lomb, began its first day as a private firm under the protective wing of Warburg Pincus. The private equity firm completed the $4.5bn buy-out of B&L (including an assumption of $830m of debt) on Friday October 26. Nasdaq trading of shares in Rochester, New York-based B&L stopped at the end of the day, closing at $64.98 before being delisted from the stock exchange. The company hopes now to rebuild its finances, which have undergone a beating over the last year after a worldwide recall in May 2006 of its best-selling multipurpose lens cleaner.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel